
Section 1 – Strategic Report 11
Gains
Trancom is a logistics company specialising in optimising supply chain operations. The company offers logistics centre
management and transport matching services. After multiple meetings with the founding family, in 2H 2024 Trancom
announced a management buyout with Bain Capital, valued at approximately 100 billion yen. As a result, the shares
increased 80.0%, contributing to 273bps of NAV performance. We agreed to tender our shares in the tender offer bid and
will be looking to re-invest some of the proceeds into the go-private special purpose company (“SPC”).
Yamaichi Electronics is one of Japan’s leading manufacturers of burn-in IC sockets, selling a consumable product used in
semiconductor testing. The company has benefited from increasing sales due to improvement in unit volume. The shares
increased 48.0% over the period, adding 187bps to performance.
Miniaturisation leads to more pins (greater volume, more revenue) per integrated chip, creating barriers to entry as it
becomes increasingly difficult to create the underlying mould for chip making. As integrated chips miniaturise, the test
sockets become more prone to short-circuiting due to the proximity of the chips. In May 2024, the company announced
strong earnings forecast, with operating profit more than doubling (up 150.0% YoY) FY23/24, driven by the recovery of test
stocks for smartphone-related chips. We used market strength to sell down our entire position, which amounted to 6.9% of
total shares outstanding, ex-treasury shares.
Hogy Medical is a leading manufacturer of medical products, focused on delivering premium surgical kits and non-woven
fabric products. The share price increased 22.0%, contributing 184bps to performance. Foreign ownership of the company,
including NAVF, exceeds 50%. We have engaged with company’s management, suggesting an improvement in capital
allocation and increased alignment of interest through restricted stock unit compensation. Valuation of the company is at
the high end for the portfolio at 8x Enterprise Value (“EV”) to its Earnings Before Interest, Taxes, Depreciation & Amortisation
(“EBITDA”), but we are compensated by the low capital expenditure nature of the business.
Bunka Shutter is Japan’s second largest company in manufacturing of shutters after Sanwa Holdings. The company
manufactures shutters used in households and warehouses. The share price increased 31.0%, contributing 178bps. We
continue to engage with the company’s management, suggesting optimisation of the business portfolio, focusing on growth,
profitability and return on invested capital (“ROIC”). We think that the company holds excessive amounts of cash and cross
shareholdings, which dilutes any efforts to improve business performance with a low return on equity (“ROE”). The company
valuation remains attractive to us, trading at sub 5x EV/EBITDA.
Murakami is a leading manufacturer of automotive rearview mirrors. The shares increased 40.0%, adding 175bps
performance to the fund. It has 40.0% domestic market share, followed by Ichiko Industries’ 21.0% and Gentex’s 28.0%.
Murakami serves the Japanese domestic original equipment manufacturers (“OEMs”), and historically, the company has
followed their customers to overseas locations when they open up a new factory. Domestic mirrors have high barriers to
entry due to aggressive demands (quality and price) by OEM and Tier 1 suppliers. Despite the 40.0% increase in the share
price, Murakami’s valuation remains attractive at sub 2x EV /EBITDA.
Detractors
Konishi produces and sells adhesives to domestic households, industrial and consumer markets. The company is also
involved in construction and public infrastructure projects. The share price declined 10.0%, contributing to a negative
23bps drag to the fund. The company trades at sub 5x EV/EBITDA, while maintaining a mid-teens ROIC in a relatively stable
business, with low capital expenditure. We own approximately 1.0% of the total shares outstanding, and will continue to
revisit sizing, depending on the opportunity set within the fund.
Tsuruha Holdings (“Tsuruha”) is one of Japan’s largest drugstore chains, operating under the name Tsuruha Drug. The
company owned over 2,500 locations across Japan as of 2024. In early February 2024, Aeon announced that it would
acquire a 13.6% stake from Oasis for Y15,500 per share, 31.5% higher than the share price at the time of announcement.
Aeon will acquire additional shares to make Tsuruha an equity method affiliate. We exited the position at a loss, as we were
not confident of Aeon’s position as a major holder of Tsuruha.
Sekisui Jushi specialises in plastic and resin-based products used in road infrastructure and urban development. The
company supplies products to government infrastructure projects. The share price declined 20.0%, as the market adjusted
for the high valuation European Merger and Acquisition (“M&A”) deal announced earlier in the year. The position
contributed a 114bps drag to the fund. The company trades at attractive valuations, trading at sub 4x EV/EBITDA. We will
continue to closely monitor the company’s ROIC, which peaked at 25.0% in 2022.